Bio-Rad Laboratories (BIO) Projected to Post Earnings on Wednesday

Bio-Rad Laboratories (NYSE:BIO) is expected to be issuing its Q3 2025 results after the market closes on Wednesday, October 29th. Analysts expect the company to announce earnings of $2.25 per share and revenue of $651.3020 million for the quarter. Bio-Rad Laboratories has set its FY 2025 guidance at EPS.Investors can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Wednesday, October 29, 2025 at 5:00 PM ET.

Bio-Rad Laboratories (NYSE:BIO) last issued its quarterly earnings results on Thursday, July 31st. The medical research company reported $2.61 earnings per share for the quarter, topping the consensus estimate of $1.93 by $0.68. Bio-Rad Laboratories had a return on equity of 4.01% and a net margin of 12.50%.The firm had revenue of $651.60 million for the quarter, compared to the consensus estimate of $614.82 million. During the same period in the prior year, the business posted $3.11 earnings per share. The company’s revenue for the quarter was up 2.1% on a year-over-year basis. On average, analysts expect Bio-Rad Laboratories to post $11 EPS for the current fiscal year and $12 EPS for the next fiscal year.

Bio-Rad Laboratories Price Performance

BIO opened at $337.05 on Tuesday. The business has a fifty day moving average of $296.41 and a 200 day moving average of $263.10. The stock has a market cap of $9.12 billion, a P/E ratio of 28.73 and a beta of 0.97. The company has a quick ratio of 3.67, a current ratio of 5.12 and a debt-to-equity ratio of 0.17. Bio-Rad Laboratories has a 52-week low of $211.43 and a 52-week high of $387.99.

Hedge Funds Weigh In On Bio-Rad Laboratories

Large investors have recently bought and sold shares of the business. Geneos Wealth Management Inc. lifted its holdings in Bio-Rad Laboratories by 115.2% during the second quarter. Geneos Wealth Management Inc. now owns 142 shares of the medical research company’s stock worth $34,000 after buying an additional 76 shares during the period. WFA of San Diego LLC purchased a new stake in shares of Bio-Rad Laboratories during the 2nd quarter worth $222,000. First Trust Advisors LP purchased a new stake in shares of Bio-Rad Laboratories during the 2nd quarter worth $270,000. Empowered Funds LLC boosted its position in Bio-Rad Laboratories by 14.8% during the first quarter. Empowered Funds LLC now owns 1,547 shares of the medical research company’s stock valued at $377,000 after purchasing an additional 199 shares in the last quarter. Finally, LMR Partners LLP purchased a new position in Bio-Rad Laboratories in the second quarter valued at about $470,000. Institutional investors own 65.24% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on BIO. Royal Bank Of Canada boosted their target price on shares of Bio-Rad Laboratories from $387.00 to $409.00 and gave the company an “outperform” rating in a research note on Friday, August 1st. Weiss Ratings reissued a “sell (d+)” rating on shares of Bio-Rad Laboratories in a research report on Tuesday, October 14th. Zacks Research upgraded shares of Bio-Rad Laboratories from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 26th. Wall Street Zen downgraded shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research note on Friday, August 22nd. Finally, Wells Fargo & Company increased their price objective on Bio-Rad Laboratories from $245.00 to $265.00 and gave the stock an “equal weight” rating in a research note on Friday, August 1st. Three equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $333.50.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.